Immunotherapy, a new era of cancer treatment

A new immuno-oncology with checkpoint inhibitors acting on non-specific T immunity by removing the brakes blocking T cells has become a clinical reality. The latest international cancer meetings have considered as encouraging and promising the data obtained in cancer immunotherapy.
Tedopi® activates specific T lymphocytes via neo-epitopes combined and optimized from several tumor antigens.

Lung cancer in numbers

Each year, the number of deaths due to lung cancer is higher than the cumulative number of deaths due to colon, breast and prostate cancer.

  • 1.58 million new cases of lung cancer, and 1.39 million deaths were recorded, worldwide, in 2012.
  • In the U.S., lung cancer affects 214,000 patients, and results in 168,000 deaths per year.
  • In Europe (28 countries), the incidence is 313,000 patients and 268,000 deaths per year.
  • In China, lung cancer affects 653,000 patients and causes 587,000 deaths, annually.
(Source: Globocan 2012)

Progress in treatment but disappointing results after 5 years.

Lung cancer – Our lead product Tedopi®

Non-small cell lung cancer (NSCLC)

Non-small cell lung cancer accounts for 85 to 88% of lung cancers. The relative five-year overall survival of this disease is 15.6%. For most patients, this cancer is discovered at an advanced stage, making it difficult to treat. In part because of its poor prognosis, NSCLC is considered as a major public health issue.

Tedopi® is developed for patients who express the HLA-A2 marker. For NSCLC, the presence of this marker is considered an aggravating risk factor at an advanced stage. Approximately 45% of the global population, and of patients with this disease, possess the HLA-A2 marker (also called “HLA-A2+”). Tedopi® may therefore potentially address nearly 84,000 patients in the USA, 134,000 in Europe and 258,000 in China.

Despite the various therapies available today (surgery, radiotherapy, chemotherapy, targeted therapy), the relative survival rate of these patients at metastatic stage is only about 1% for those with lung cancer NSCLC. The need for effective and well tolerated treatments remains strong.

Tedopi® by OSE Immunotherapeutics, a new activation immunotherapy developed for NSCLC cancer

Tedopi®, developed for the treatment of non-small cell lung cancer (NSCLC), works by stimulating the body’s T cytotoxic “killer” cells and reprogramming them to spot malignant cells for elimination. These are the steps that encompass the immunosurveillance process.

Tedopi® is a patented combination of neo-10 epitopes selected and optimized from five tumorous antigens. These 10 neo-epitopes generate a specific response from the T cytotoxic cells against the malignant cells which express at least one of these tumorous antigens. The selected epitopes are chemically optimized and combined to avoid any phenomenon of immune tolerance. Tedopi® is a personalized treatment for HLA-A2+ patients.

The goal is to stabilize the development of the disease and to extend patients’ lives.

Data generated from a Phase 2 clinical trial showed that Tedopi® was effective in treating NSCLC, by increasing the relative survival rate.

More about clinical trials of Tedopi ® and the results recorded

Current treatments and applications of Tedopi®, AT VARIOUS stages of the disease.

Treatments available for NSCLC lung cancer vary, depending on the stage of disease.

  • Evolution stage Ia: – surgery, consisting of removing either the affected part of the lung or the whole lung. If surgery is not possible, radiotherapy is recommended;
  • Evolution stage Ib: surgery, possibly followed by chemotherapy. If surgery is not possible, radiotherapy is recommended;
  • Evolution stage Ia and IIb: surgery followed by chemotherapy. If surgery is not possible, radiotherapy is recommended;
  • Evolution stage IIIa: chemotherapy, possibly combined with surgery or radiotherapy;
  • Evolution stage IIIb: chemotherapy combined with radiotherapy, surgery is an exception;
  • Evolution stage IV: chemotherapy may be combined with other types of treatments (“targeted therapy” on particular mutations for instance).

Tedopi® is currently being evaluated in a Phase 3 clinical trial, Atalante 1, for patients in stages IIIb and IV, and as a second or third line therapy.